Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.40 |
| ▸ | FADS1 | O60427 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7460584 | 0.89 | GRM2 (0.52) | GRM2MAOAFADS1HDAC1HDAC8 | |
| SCHEMBL8892005 | 0.87 | GRM2 (0.51) | GRM2MAOAFADS1HDAC1HDAC8 | |
| SCHEMBL5762328 | 0.80 | GRM2 (0.53) | GRM2MAOASIRT2SIRT1FADS1 | |
| SCHEMBL2795377 | 0.79 | MAOA (0.60) | MAOASIRT2SIRT1FADS1 | |
| SCHEMBL2800366 | 0.79 | MAOA (0.49) | MAOA | |
| SCHEMBL8948817 | 0.77 | GRM2 (0.65) | GRM2MAOA | |
| SCHEMBL8948639 | 0.77 | GRM2 (0.65) | GRM2MAOA | |
| SCHEMBL2798691 | 0.77 | GRM2 (0.65) | GRM2 | |
| SCHEMBL13515441 | 0.77 | MAOA (0.55) | MAOAPOLBALDH1A1 | |
| SCHEMBL7237979 | 0.77 | GRM2 (0.65) | GRM2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288423-B2 | FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof | LEGOCHEM BIOSCIENCE LTD. (KR) | 2012-10-16 | — | — | US | disclosed |
| US-20100184781-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-07-22 | — | — | US | disclosed |
| WO-2008140220-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184781-A1 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF | F12, F2, TFPI | GRM2 4803/4885MAOA 1142/4885SIRT2 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.